We are hosting a private investor briefing with IGC Pharma (NYSE American: IGC), a clinical-stage biotechnology and AI company developing novel therapeutics and predictive intelligence platforms focused on Alzheimer’s disease.
Company Overview
IGC Pharma is a clinical-stage biotechnology and AI company focused on developing innovative solutions for Alzheimer’s disease. The company’s lead therapeutic candidate, IGC-AD1, is currently advancing towards a Phase 2 clinical trial topline readout targeting agitation in Alzheimer’s disease (AAD), a significant unmet need affecting millions of patients worldwide.
With a topline readout from the Phase 2 (n=170) trial expected in the coming months, IGC Pharma is positioned at a potential valuation inflection of 5 to 15X from current valuations based on market peers.
Key Highlights
Phase 2 clinical trial 100% enrolled and nearing completion of dosing and database lock and topline readout.
Addressing a significant unmet need in Alzheimer’s disease, a market affecting more than 40 million people globally
Lead therapeutic candidate designed to improve upon limitations of current treatment options
AI-powered Alzheimer’s foundation platform creating additional growth opportunities beyond therapeutics
Positioned at the intersection of biotechnology, artificial intelligence, and aging-related healthcare innovation
Opportunity to invest in a publicly traded company with a current valuation significantly below comparable Alzheimer’s-focused biotech companies, and significantly below a positive Phase 2 readout.
